Literature DB >> 34455538

Savolitinib: First Approval.

Anthony Markham1.   

Abstract

Savolitinib (Orpathys®; HUTCHMED, AstraZeneca) is a receptor tyrosine kinase mesenchymal epithelial transition factor (MET) inhibitor being developed for the treatment of metastatic non-small cell lung cancer (NSCLC), papillary and clear cell renal cell carcinoma (RCC), gastric cancer and colorectal cancer. Based on the results of a pivotal phase II trial in patients with NSCLC/pulmonary sarcomatoid carcinoma, savolitinib was recently granted approval in China (conditional on the results of a phase III trial) for the treatment of metastatic NSCLC with MET exon 14-skipping alterations in patients who have progressed after or who are unable to tolerate platinum-based chemotherapy. This article summarizes the milestones in the development of savolitinib leading to this first approval.
© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34455538     DOI： 10.1007/s40265-021-01584-0

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


  3 in total

1.  Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial.

Authors:  Seung Tae Kim; Kyung Kim; Hyuk Lee; Iwanka Kozarewa; Jeeyun Lee; Peter G S Mortimer; Justin I Odegaard; Elizabeth A Harrington; Juyoung Lee; Taehyang Lee; Sung Yong Oh; Jung-Hun Kang; Jung Hoon Kim; Youjin Kim; Jun Ho Ji; Young Saing Kim; Kyoung Eun Lee; Jinchul Kim; Tae Sung Sohn; Ji Yeong An; Min-Gew Choi; Jun Ho Lee; Jae Moon Bae; Sung Kim; Jae J Kim; Yang Won Min; Byung-Hoon Min; Nayoung K D Kim; Sally Luke; Young Hwa Kim; Jung Yong Hong; Se Hoon Park; Joon Oh Park; Young Suk Park; Ho Yeong Lim; AmirAli Talasaz; Simon J Hollingsworth; Kyoung-Mee Kim; Won Ki Kang
Journal:  Cancer Discov       Date:  2019-07-17       Impact factor: 39.397

2.  Effect of food on the single-dose pharmacokinetics and tolerability of savolitinib in Chinese healthy volunteers.

Authors:  Qichen Ding; Meixian Ou; Huijuan Zhu; Yijun Wang; Jingying Jia; Yang Sai; Qian Chen; Jian Wang
Journal:  Fundam Clin Pharmacol       Date:  2021-06-16       Impact factor: 2.748

3.  Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study.

Authors:  Shun Lu; Jian Fang; Xingya Li; Lejie Cao; Jianying Zhou; Qisen Guo; Zongan Liang; Ying Cheng; Liyan Jiang; Nong Yang; Zhigang Han; Jianhua Shi; Yuan Chen; Hua Xu; Helong Zhang; Gongyan Chen; Rui Ma; Sanyuan Sun; Yun Fan; Jing Li; Xian Luo; Linfang Wang; Yongxin Ren; Weiguo Su
Journal:  Lancet Respir Med       Date:  2021-06-21       Impact factor: 30.700
  3 in total
  9 in total

Review 1.  Signaling pathways and therapeutic interventions in gastric cancer.

Authors:  Zi-Ning Lei; Qiu-Xu Teng; Qin Tian; Wei Chen; Yuhao Xie; Kaiming Wu; Qianlin Zeng; Leli Zeng; Yihang Pan; Zhe-Sheng Chen; Yulong He
Journal:  Signal Transduct Target Ther       Date:  2022-10-08

2.  Case Report: Sequential Combination Targeted Therapy With Type I and II MET Inhibitors in a Metastatic EGFR-Mutated, MET-Amplified NSCLC Patient With Acquired MET Y1230H Mutation.

Authors:  Boning Cai; Xiaomo Li; Xiang Huang; Tonghui Ma; Baolin Qu; Wei Yu; Wei Yang; Pei Zhang; Jing Chen; Fang Liu
Journal:  Front Oncol       Date:  2021-12-02       Impact factor: 6.244

Review 3.  Multimodality Treatment of Pulmonary Sarcomatoid Carcinoma: A Review of Current State of Art.

Authors:  Lin Zhang; Weihao Lin; Zhenlin Yang; Renda Li; Yibo Gao; Jie He
Journal:  J Oncol       Date:  2022-03-25       Impact factor: 4.375

Review 4.  The dawn of precision medicine in diffuse-type gastric cancer.

Authors:  Akira Ooki; Kensei Yamaguchi
Journal:  Ther Adv Med Oncol       Date:  2022-03-08       Impact factor: 8.168

5.  Case Report: Prompt Response to Savolitinib in a Case of Advanced Gastric Cancer With Bone Marrow Invasion and MET Abnormalities.

Authors:  Wen Ye; Liping He; Lei Su; Zhousan Zheng; Meilin Ding; Sheng Ye
Journal:  Front Oncol       Date:  2022-04-04       Impact factor: 5.738

Review 6.  Syntheses and Applications of 1,2,3-Triazole-Fused Pyrazines and Pyridazines.

Authors:  Gavin R Hoffman; Allen M Schoffstall
Journal:  Molecules       Date:  2022-07-22       Impact factor: 4.927

7.  Neoadjuvant Savolitinib targeted therapy stage IIIA-N2 primary lung adenocarcinoma harboring MET Exon 14 skipping mutation: A case report.

Authors:  Meng Fu; Chun-Mei Feng; Da-Qing Xia; Zi-Mei Ji; Huai-Ling Xia; Na-Na Hu; Zai-Jun Leng; Wang Xie; Yuan Fang; Le-Jie Cao; Jun-Qiang Zhang
Journal:  Front Oncol       Date:  2022-08-16       Impact factor: 5.738

8.  Use of savolitinib as neoadjuvant therapy for non-small cell lung cancer patient with MET exon 14 skipping alterations: A case report.

Authors:  Yu Zhang; Hao Zhang; Hanqing Wang; Jingtong Zeng; Bo Zhang; Ning Zhou; Lingling Zu; Zuoqing Song; Changli Wang; Song Xu
Journal:  Front Oncol       Date:  2022-09-08       Impact factor: 5.738

9.  Management of Peripheral Edema in Patients with MET Exon 14-Mutated Non-small Cell Lung Cancer Treated with Small Molecule MET Inhibitors.

Authors:  Makoto Nishio; Terufumi Kato; Ryo Toyozawa; Toyoaki Hida
Journal:  Target Oncol       Date:  2022-09-10       Impact factor: 4.864
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.